Review
. 2016 Feb;11(2).
doi: 10.1371/journal.pone.0149803.

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

Miranta Antoniou 1 Andrea L Jorgensen 1 Ruwanthi Kolamunnage-Dona 1 
Affiliations
  • PMID: 26910238
  •     123 References
  •     23 citations

Abstract

Background: Personalized medicine is a growing area of research which aims to tailor the treatment given to a patient according to one or more personal characteristics. These characteristics can be demographic such as age or gender, or biological such as a genetic or other biomarker. Prior to utilizing a patient's biomarker information in clinical practice, robust testing in terms of analytical validity, clinical validity and clinical utility is necessary. A number of clinical trial designs have been proposed for testing a biomarker's clinical utility, including Phase II and Phase III clinical trials which aim to test the effectiveness of a biomarker-guided approach to treatment; these designs can be broadly classified into adaptive and non-adaptive. While adaptive designs allow planned modifications based on accumulating information during a trial, non-adaptive designs are typically simpler but less flexible.

Methods And Findings: We have undertaken a comprehensive review of biomarker-guided adaptive trial designs proposed in the past decade. We have identified eight distinct biomarker-guided adaptive designs and nine variations from 107 studies. Substantial variability has been observed in terms of how trial designs are described and particularly in the terminology used by different authors. We have graphically displayed the current biomarker-guided adaptive trial designs and summarised the characteristics of each design.

Conclusions: Our in-depth overview provides future researchers with clarity in definition, methodology and terminology for biomarker-guided adaptive trial designs.

Trials within trials: confirmatory subgroup analyses in controlled clinical experiments.
L A Moyé, A Deswal.
Control Clin Trials, 2001 Dec 12; 22(6). PMID: 11738119
Review.
Seamlessly expanding a randomized phase II trial to phase III.
Lurdes Y T Inoue, Peter F Thall, Donald A Berry.
Biometrics, 2002 Dec 24; 58(4). PMID: 12495136
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.
Patrick Royston, Mahesh K B Parmar, Wendi Qian.
Stat Med, 2003 Jul 11; 22(14). PMID: 12854091
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Larry J Copeland, Michael Bookman, Edward Trimble, Gynecologic Oncology Group Protocol GOG 182-ICON5.
Gynecol Oncol, 2003 Aug 21; 90(2 Pt 2). PMID: 12927999
Clinical trial designs for predictive marker validation in cancer treatment trials.
Daniel J Sargent, Barbara A Conley, Carmen Allegra, Laurence Collette.
J Clin Oncol, 2005 Mar 19; 23(9). PMID: 15774793
Highly Cited. Review.
Statistical consideration of adaptive methods in clinical development.
Shein-Chung Chow, Mark Chang, Annpey Pong.
J Biopharm Stat, 2005 Jul 19; 15(4). PMID: 16022164
One- and two-stage designs for stratified phase II clinical trials.
Wendy B London, Myron N Chang.
Stat Med, 2005 Aug 25; 24(17). PMID: 16118809
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Boris Freidlin, Richard Simon.
Clin Cancer Res, 2005 Nov 10; 11(21). PMID: 16278411
Bayesian clinical trials.
Donald A Berry.
Nat Rev Drug Discov, 2006 Feb 18; 5(1). PMID: 16485344
Highly Cited. Review.
Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
Paul Gallo, Christy Chuang-Stein, +4 authors, PhRMA Working Group.
J Biopharm Stat, 2006 May 27; 16(3). PMID: 16724485
An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.
Cheryl L Jones, Eric Holmgren.
Contemp Clin Trials, 2007 Apr 07; 28(5). PMID: 17412647
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Wenyu Jiang, Boris Freidlin, Richard Simon.
J Natl Cancer Inst, 2007 Jun 29; 99(13). PMID: 17596577
Multiplicity and flexibility in clinical trials.
Werner Brannath, Franz Koenig, Peter Bauer.
Pharm Stat, 2007 Aug 04; 6(3). PMID: 17674349
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.
Sue-Jane Wang, Robert T O'Neill, H M James Hung.
Pharm Stat, 2007 Aug 11; 6(3). PMID: 17688238
Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer.
Lajos Pusztai, Keith Anderson, Kenneth R Hess.
Clin Cancer Res, 2007 Oct 20; 13(20). PMID: 17947471
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
Sue-Jane Wang.
Pharm Stat, 2007 Oct 25; 6(4). PMID: 17957727
Adaptive seamless designs: selection and prospective testing of hypotheses.
Christopher Jennison, Bruce W Turnbull.
J Biopharm Stat, 2007 Nov 21; 17(6). PMID: 18027222
Review.
Statistical analysis for two-stage seamless design with different study endpoints.
Shein-Chung Chow, Qingshu Lu, Siu-Keung Tse.
J Biopharm Stat, 2007 Nov 21; 17(6). PMID: 18027223
Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
H M James Hung, Sue-Jane Wang, Robert O'Neill.
J Biopharm Stat, 2007 Nov 21; 17(6). PMID: 18027226
Advances and challenges in the use of biomarkers in clinical trials.
Bruce Chabner.
Clin Adv Hematol Oncol, 2008 Mar 07; 6(1). PMID: 18322440
Review.
Adaptive design methods in clinical trials - a review.
Shein-Chung Chow, Mark Chang.
Orphanet J Rare Dis, 2008 May 06; 3. PMID: 18454853    Free PMC article.
Review.
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
Xian Zhou, Suyu Liu, +2 authors, J Jack Lee.
Clin Trials, 2008 Jun 19; 5(3). PMID: 18559407    Free PMC article.
Adaptive clinical trials: progress and challenges.
Christopher S Coffey, John A Kairalla.
Drugs R D, 2008 Jul 01; 9(4). PMID: 18588354
Review.
Randomized phase III clinical trial designs for targeted agents.
Antje Hoering, Mike Leblanc, John J Crowley.
Clin Cancer Res, 2008 Jul 17; 14(14). PMID: 18628448    Free PMC article.
Group sequential and adaptive designs - a review of basic concepts and points of discussion.
Marc Vandemeulebroecke.
Biom J, 2008 Jul 30; 50(4). PMID: 18663761
Review.
Speeding up the evaluation of new agents in cancer.
Mahesh K B Parmar, Friederike M-S Barthel, +9 authors, Patrick Royston.
J Natl Cancer Inst, 2008 Aug 30; 100(17). PMID: 18728279    Free PMC article.
Statistical issues in translational cancer research.
Stephen L George.
Clin Cancer Res, 2008 Oct 03; 14(19). PMID: 18829473
Review.
The use of genomics in clinical trial design.
Richard Simon.
Clin Cancer Res, 2008 Oct 03; 14(19). PMID: 18829477
Review.
Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
Sue-Jane Wang.
J Formos Med Assoc, 2009 Mar 31; 107(12 Suppl). PMID: 19129042
On Two-stage Seamless Adaptive Design in Clinical Trials.
Shein-Chung Chow, Yi-Hsuan Tu.
J Formos Med Assoc, 2009 Mar 31; 107(12 Suppl). PMID: 19129046
Biomarkers and surrogates in clinical studies.
Claudio Rigatto, Brendan J Barrett.
Methods Mol Biol, 2009 Jan 24; 473. PMID: 19160736
Review.
Development and Validation of Biomarker Classifiers for Treatment Selection.
Richard Simon.
J Stat Plan Inference, 2009 Feb 05; 138(2). PMID: 19190712    Free PMC article.
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Werner Brannath, Emmanuel Zuber, +4 authors, Amy Racine-Poon.
Stat Med, 2009 Mar 07; 28(10). PMID: 19266565
Effective incorporation of biomarkers into phase II trials.
Lisa M McShane, Sally Hunsberger, Alex A Adjei.
Clin Cancer Res, 2009 Mar 12; 15(6). PMID: 19276274    Free PMC article.
Review.
Adaptive patient enrichment designs in therapeutic trials.
Sue-Jane Wang, H M James Hung, Robert T O'Neill.
Biom J, 2009 Apr 10; 51(2). PMID: 19358222
How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials.
F M-S Barthel, M K B Parmar, P Royston.
Trials, 2009 Apr 21; 10. PMID: 19374739    Free PMC article.
Clinical trial designs for predictive biomarker validation: one size does not fit all.
Sumithra J Mandrekar, Daniel J Sargent.
J Biopharm Stat, 2009 Apr 23; 19(3). PMID: 19384694    Free PMC article.
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
A D Barker, C C Sigman, +3 authors, L J Esserman.
Clin Pharmacol Ther, 2009 May 15; 86(1). PMID: 19440188
Highly Cited.
Molecular biomarkers to individualise treatment: assessing the evidence.
Chee K Lee, Sarah J Lord, Alan S Coates, R John Simes.
Med J Aust, 2009 Jun 03; 190(11). PMID: 19485842
Review.
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
Matthew R Sydes, Mahesh K B Parmar, +6 authors, Patrick Royston.
Trials, 2009 Jun 13; 10. PMID: 19519885    Free PMC article.
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
Sumithra J Mandrekar, Daniel J Sargent.
J Clin Oncol, 2009 Jul 15; 27(24). PMID: 19597023    Free PMC article.
Highly Cited.
Methodological aspects of lung cancer clinical trials in the era of targeted agents.
Massimo Di Maio, Ciro Gallo, +4 authors, Francesco Perrone.
Lung Cancer, 2009 Oct 31; 67(2). PMID: 19875193
Review.
Genomic markers for decision making: what is preventing us from using markers?
Vicky M Coyle, Patrick G Johnston.
Nat Rev Clin Oncol, 2009 Dec 17; 7(2). PMID: 20010899
Review.
The cross-validated adaptive signature design.
Boris Freidlin, Wenyu Jiang, Richard Simon.
Clin Cancer Res, 2010 Jan 14; 16(2). PMID: 20068112
Phase II clinical trials in oncology: are we hitting the target?
Mei-Kim Ang, Say-Beng Tan, Wan-Teck Lim.
Expert Rev Anticancer Ther, 2010 Mar 11; 10(3). PMID: 20214523
Review.
Clinical trials for predictive medicine: new challenges and paradigms.
Richard Simon.
Clin Trials, 2010 Mar 27; 7(5). PMID: 20338899    Free PMC article.
Biomarkers and surrogate end points--the challenge of statistical validation.
Marc Buyse, Daniel J Sargent, +2 authors, Aimery de Gramont.
Nat Rev Clin Oncol, 2010 Apr 07; 7(6). PMID: 20368727
Review.
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.
Richard Simon.
Per Med, 2010 Apr 13; 7(1). PMID: 20383292    Free PMC article.
Predictive biomarker validation in practice: lessons from real trials.
Sumithra J Mandrekar, Daniel J Sargent.
Clin Trials, 2010 Apr 16; 7(5). PMID: 20392785    Free PMC article.
Biostatistic tools in pharmacogenomics--advances, challenges, potential.
Yasunori Sato, Nan M Laird, Teruhiko Yoshida.
Curr Pharm Des, 2010 May 13; 16(20). PMID: 20459388
Review.
Biomarkers and the design of clinical trials in cancer.
Graeme A M Fraser, Ralph M Meyer.
Biomark Med, 2007 Oct 01; 1(3). PMID: 20477382
Bayesian adaptive randomization designs for targeted agent development.
J Jack Lee, Xuemin Gu, Suyu Liu.
Clin Trials, 2010 Jun 24; 7(5). PMID: 20571130    Free PMC article.
A Bayesian adaptive design with biomarkers for targeted therapies.
Jens C Eickhoff, KyungMann Kim, +2 authors, Jason R Gee.
Clin Trials, 2010 Jun 24; 7(5). PMID: 20571131    Free PMC article.
The efficiency of clinical trial designs for predictive biomarker validation.
K Y Young, A Laird, X H Zhou.
Clin Trials, 2010 Jun 24; 7(5). PMID: 20571132
Design, operation, and interpretation of clinical trials.
B L Pihlstrom, M L Barnett.
J Dent Res, 2010 Jun 29; 89(8). PMID: 20581353
Review.
A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations.
Aiyi Liu, Chunling Liu, +2 authors, Vivian W Yuan.
Clin Trials, 2010 Aug 06; 7(5). PMID: 20685769    Free PMC article.
An introduction to adaptive designs and adaptation in CNS trials.
Vladimir Dragalin.
Eur Neuropsychopharmacol, 2010 Oct 05; 21(2). PMID: 20888739
Review.
Adaptive design clinical trials: Methodology, challenges and prospect.
Rajiv Mahajan, Kapil Gupta.
Indian J Pharmacol, 2010 Oct 12; 42(4). PMID: 20927243    Free PMC article.
Adaptive design clinical trials and trial logistics models in CNS drug development.
Sue-Jane Wang, H M James Hung, Robert O'Neill.
Eur Neuropsychopharmacol, 2010 Oct 12; 21(2). PMID: 20933373
Review.
Adaptive methods: telling "the rest of the story".
Scott S Emerson, Thomas R Fleming.
J Biopharm Stat, 2010 Nov 09; 20(6). PMID: 21058111
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
Evanthia Galanis, Wenting Wu, +4 authors, David A Reardon.
Curr Oncol Rep, 2010 Dec 03; 13(1). PMID: 21125354    Free PMC article.
Review.
Biomarker-adaptive clinical trial designs.
Boris Freidlin, Edward L Korn.
Pharmacogenomics, 2010 Dec 15; 11(12). PMID: 21142910
Outcome--adaptive randomization: is it useful?
Edward L Korn, Boris Freidlin.
J Clin Oncol, 2010 Dec 22; 29(6). PMID: 21172882    Free PMC article.
Implementing prognostic and predictive biomarkers in CRC clinical trials.
Sandra Van Schaeybroeck, Wendy L Allen, Richard C Turkington, Patrick G Johnston.
Nat Rev Clin Oncol, 2011 Feb 16; 8(4). PMID: 21321566
Review.
Integrating biomarkers in clinical trials.
Marc Buyse, Stefan Michiels, +3 authors, Aimery de Gramont.
Expert Rev Mol Diagn, 2011 Mar 17; 11(2). PMID: 21405968
Review.
Innovative approaches to clinical development and trial design.
John J Orloff, Donald Stanski.
Ann Ist Super Sanita, 2011 Mar 25; 47(1). PMID: 21430331
Review.
Targeting population entering phase III trials: a new stratified adaptive phase II design.
Caroline Tournoux-Facon, Yann De Rycke, Pascale Tubert-Bitter.
Stat Med, 2011 Mar 25; 30(8). PMID: 21432875
Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings.
Sarah C Emerson, Kyle D Rudser, Scott S Emerson.
Stat Med, 2011 May 04; 30(11). PMID: 21538450    Free PMC article.
The BATTLE to personalize lung cancer prevention through reverse migration.
Kathryn A Gold, Edward S Kim, +3 authors, Waun Ki Hong.
Cancer Prev Res (Phila), 2011 Jul 08; 4(7). PMID: 21733820    Free PMC article.
Vasopressors and the search for the optimal trial design.
Ritesh Maharaj.
Contemp Clin Trials, 2011 Aug 03; 32(6). PMID: 21807122
Review.
Statistical considerations for the next generation of clinical trials.
Wenting Wu, Qian Shi, Daniel J Sargent.
Semin Oncol, 2011 Aug 04; 38(4). PMID: 21810519
Review.
Integrating predictive biomarkers and classifiers into oncology clinical development programmes.
Robert A Beckman, Jason Clark, Cong Chen.
Nat Rev Drug Discov, 2011 Oct 01; 10(10). PMID: 21959287
Review.
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
Howard I Scher, Shelley Fuld Nasso, Eric H Rubin, Richard Simon.
Clin Cancer Res, 2011 Nov 03; 17(21). PMID: 22046024    Free PMC article.
Adaptive clinical trials in oncology.
Donald A Berry.
Nat Rev Clin Oncol, 2011 Nov 09; 9(4). PMID: 22064459
Review.
Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.
Qian Shi, Sumithra J Mandrekar, Daniel J Sargent.
Scand J Gastroenterol, 2011 Dec 21; 47(3). PMID: 22181041
Review.
A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
Stella Wanjugu Karuri, Richard Simon.
Stat Med, 2012 Jan 13; 31(10). PMID: 22238151
Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.
Donald A Berry, Roy S Herbst, Eric H Rubin.
Clin Cancer Res, 2012 Feb 03; 18(3). PMID: 22298897    Free PMC article.
Cancer biomarkers: selecting the right drug for the right patient.
Gary J Kelloff, Caroline C Sigman.
Nat Rev Drug Discov, 2012 Feb 11; 11(3). PMID: 22322254
Highly Cited. Review.
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Martin Jenkins, Andrew Stone, Christopher Jennison.
Pharm Stat, 2012 Feb 14; 10(4). PMID: 22328327
Design of clinical trials for biomarker research in oncology.
Sumithra J Mandrekar, Daniel J Sargent.
Clin Investig (Lond), 2012 Mar 06; 1(12). PMID: 22389760    Free PMC article.
Clinical trial designs for testing biomarker-based personalized therapies.
Tze Leung Lai, Philip W Lavori, Mei-Chiung I Shih, Branimir I Sikic.
Clin Trials, 2012 Mar 09; 9(2). PMID: 22397801    Free PMC article.
Biomarkers, subgroup evaluation, and clinical trial design.
Stuart G Baker, Barnett S Kramer, Daniel J Sargent, Marco Bonetti.
Discov Med, 2012 Apr 03; 13(70). PMID: 22463794
Review.
A 2-stage phase II design with direct assignment option in stage II for initial marker validation.
Ming-Wen An, Sumithra J Mandrekar, Daniel J Sargent.
Clin Cancer Res, 2012 Jun 16; 18(16). PMID: 22700865    Free PMC article.
Bayesian clinical trials in action.
J Jack Lee, Caleb T Chu.
Stat Med, 2012 Jun 20; 31(25). PMID: 22711340    Free PMC article.
Review.
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.
Tony W Ho, Eric Pearlman, +12 authors, Rizatriptan Protocol 082 Pediatric Migraine Study Group.
Cephalalgia, 2012 Jun 20; 32(10). PMID: 22711898
Clinical trials for predictive medicine.
Richard Simon.
Stat Med, 2012 Jun 21; 31(25). PMID: 22714719
Current development in clinical trials: issues old and new.
David L DeMets.
Stat Med, 2012 Jun 28; 31(25). PMID: 22736410
Incorporating biomarkers into clinical trial designs: points to consider.
Edward Bradley.
Nat Biotechnol, 2012 Jul 12; 30(7). PMID: 22781677
Optimal design of multi-arm multi-stage trials.
James M S Wason, Thomas Jaki.
Stat Med, 2012 Jul 25; 31(30). PMID: 22826199
Randomized phase II trial designs with biomarkers.
Boris Freidlin, Lisa M McShane, Mei-Yin C Polley, Edward L Korn.
J Clin Oncol, 2012 Aug 08; 30(26). PMID: 22869885    Free PMC article.
Adaptive trial designs: a review of barriers and opportunities.
John A Kairalla, Christopher S Coffey, Mitchell A Thomann, Keith E Muller.
Trials, 2012 Aug 25; 13. PMID: 22917111    Free PMC article.
Review.
From drug discovery to biomarker-driven clinical trials in lymphoma.
Anas Younes, Donald A Berry.
Nat Rev Clin Oncol, 2012 Sep 12; 9(11). PMID: 22965151    Free PMC article.
Review.
Study designs and statistical analyses for biomarker research.
Masahiko Gosho, Kengo Nagashima, Yasunori Sato.
Sensors (Basel), 2012 Sep 27; 12(7). PMID: 23012528    Free PMC article.
Review.
Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer.
Roberta Ferraldeschi, Gerhardt Attard, Johann S de Bono.
Clin Chem, 2012 Dec 04; 59(1). PMID: 23204221
Review.
Omics-based clinical trial designs.
Marc Buyse, Stefan Michiels.
Curr Opin Oncol, 2013 Mar 12; 25(3). PMID: 23475192
Review.
Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics.
Richard Simon.
Expert Opin Med Diagn, 2008 Jun 01; 2(6). PMID: 23495781
Adaptive enrichment designs for clinical trials.
Noah Simon, Richard Simon.
Biostatistics, 2013 Mar 26; 14(4). PMID: 23525452    Free PMC article.
Phase III clinical trials that integrate treatment and biomarker evaluation.
Boris Freidlin, Zhuoxin Sun, Robert Gray, Edward L Korn.
J Clin Oncol, 2013 Apr 10; 31(25). PMID: 23569306    Free PMC article.
Design of oncology clinical trials: a review.
Revathi Ananthakrishnan, Sandeep Menon.
Crit Rev Oncol Hematol, 2013 Apr 30; 88(1). PMID: 23623356
Review.
A review of phase II trial designs for initial marker validation.
Sumithra J Mandrekar, Ming-Wen An, Daniel J Sargent.
Contemp Clin Trials, 2013 May 15; 36(2). PMID: 23665336    Free PMC article.
Review.
Genomic biomarkers for personalized medicine: development and validation in clinical studies.
Shigeyuki Matsui.
Comput Math Methods Med, 2013 May 22; 2013. PMID: 23690882    Free PMC article.
Review.
Trial designs for personalizing cancer care: a systematic review and classification.
Parvin Tajik, Aleiko H Zwinderman, Ben W Mol, Patrick M Bossuyt.
Clin Cancer Res, 2013 Jun 22; 19(17). PMID: 23788580
Systematic Review.
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.
Brian M Alexander, Patrick Y Wen, +4 authors, Donald A Berry.
Neuro Oncol, 2013 Jul 17; 15(8). PMID: 23857706    Free PMC article.
Review.
Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research.
Tze Leung Lai, Olivia Yueh-Wen Liao, Dong Woo Kim.
Contemp Clin Trials, 2013 Sep 03; 36(2). PMID: 23994669    Free PMC article.
Marker Sequential Test (MaST) design.
Boris Freidlin, Edward L Korn, Robert Gray.
Clin Trials, 2013 Oct 03; 11(1). PMID: 24085774
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Mei-Yin C Polley, Boris Freidlin, +3 authors, Lisa M McShane.
J Natl Cancer Inst, 2013 Oct 19; 105(22). PMID: 24136891    Free PMC article.
Evaluating many treatments and biomarkers in oncology: a new design.
Richard Kaplan, Timothy Maughan, +4 authors, Mahesh Parmar.
J Clin Oncol, 2013 Nov 20; 31(36). PMID: 24248692    Free PMC article.
Biomarker enrichment strategies: matching trial design to biomarker credentials.
Boris Freidlin, Edward L Korn.
Nat Rev Clin Oncol, 2013 Nov 28; 11(2). PMID: 24281059
Review.
A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
James M S Wason, Lorenzo Trippa.
Stat Med, 2014 Jan 15; 33(13). PMID: 24421053
Adaptive clinical trial design.
Shein-Chung Chow.
Annu Rev Med, 2014 Jan 16; 65. PMID: 24422576
Review.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Precision medicine clinical trials: defining new treatment strategies.
Brandy M Heckman-Stoddard, Judith J Smith.
Semin Oncol Nurs, 2014 May 06; 30(2). PMID: 24794084    Free PMC article.
Review.
Methodology of clinical trials for rare diseases.
Catrin Tudur Smith, Paula R Williamson, Michael W Beresford.
Best Pract Res Clin Rheumatol, 2014 Jun 30; 28(2). PMID: 24974061
Review.
Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
Cyrus Mehta, Helmut Schäfer, Hanna Daniel, Sebastian Irle.
Stat Med, 2014 Aug 19; 33(26). PMID: 25130879
Biomarker based clinical trial design.
Richard Simon.
Chin Clin Oncol, 2015 Apr 07; 3(3). PMID: 25841465
Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Ja-An Lin, Pei He.
Br Med Bull, 2015 Apr 30; 114(1). PMID: 25921239
Review.
A Bayesian adaptive design for biomarker trials with linked treatments.
James M S Wason, Jean E Abraham, +5 authors, Adrian P Mander.
Br J Cancer, 2015 Aug 12; 113(5). PMID: 26263479    Free PMC article.
Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials.
Munyaradzi Dimairo, Jonathan Boote, +2 authors, Susan Todd.
Trials, 2015 Sep 30; 16. PMID: 26416387    Free PMC article.
Optimal two-stage designs for phase II clinical trials.
R Simon.
Control Clin Trials, 1989 Mar 01; 10(1). PMID: 2702835
Highly Cited.
Clinical trials for precision oncology using next-generation sequencing.
Richard Simon, Eric Polley.
Per Med, 2013 Jul 01; 10(5). PMID: 29758837
An efficient design for phase III studies of combination chemotherapies.
S S Ellenberg, M A Eisenberger.
Cancer Treat Rep, 1985 Oct 01; 69(10). PMID: 4042093
One-sample multiple testing procedure for phase II clinical trials.
T R Fleming.
Biometrics, 1982 Mar 01; 38(1). PMID: 7082756
Highly Cited.
A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.
P F Thall, R Simon.
Control Clin Trials, 1994 Dec 01; 15(6). PMID: 7851108
The Importance of Biopsy in the Era of Molecular Medicine.
Etay Ziv, Jeremy C Durack, Stephen B Solomon.
Cancer J, 2016 Nov 22; 22(6). PMID: 27870685    Free PMC article.
Review.
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Miranta Antoniou, Ruwanthi Kolamunnage-Dona, Andrea L Jorgensen.
J Pers Med, 2017 Jan 27; 7(1). PMID: 28125057    Free PMC article.
Review.
Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.
Ignacio Segarra, Pilar Modamio, Cecilia Fernández, Eduardo L Mariño.
Front Pharmacol, 2017 Aug 09; 8. PMID: 28785221    Free PMC article.
Review.
Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size.
Miranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-Dona.
J Pers Med, 2017 Dec 07; 7(4). PMID: 29207572    Free PMC article.
Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov.
Laura E Bothwell, Jerry Avorn, Nazleen F Khan, Aaron S Kesselheim.
BMJ Open, 2018 Feb 15; 8(2). PMID: 29440155    Free PMC article.
Review.
Adaptive designs in clinical trials: why use them, and how to run and report them.
Philip Pallmann, Alun W Bedding, +13 authors, Thomas Jaki.
BMC Med, 2018 Mar 02; 16(1). PMID: 29490655    Free PMC article.
Highly Cited.
Critical concepts in adaptive clinical trials.
Jay Jh Park, Kristian Thorlund, Edward J Mills.
Clin Epidemiol, 2018 Apr 03; 10. PMID: 29606891    Free PMC article.
Review.
Point estimation following two-stage adaptive threshold enrichment clinical trials.
Peter K Kimani, Susan Todd, Lindsay A Renfro, Nigel Stallard.
Stat Med, 2018 Jun 02; 37(22). PMID: 29855066    Free PMC article.
Subgroup identification in clinical trials via the predicted individual treatment effect.
Nicolás M Ballarini, Gerd K Rosenkranz, +2 authors, Martin Posch.
PLoS One, 2018 Oct 20; 13(10). PMID: 30335831    Free PMC article.
Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.
Danielle Johnson, Dyfrig Hughes, Munir Pirmohamed, Andrea Jorgensen.
J Pers Med, 2019 Sep 05; 9(3). PMID: 31480618    Free PMC article.
Review.
Biomarker-guided trials: Challenges in practice.
M Antoniou, R Kolamunnage-Dona, +7 authors, A L Jorgensen.
Contemp Clin Trials Commun, 2019 Dec 04; 16. PMID: 31788574    Free PMC article.
Precision medicine in cardiology.
Elliott M Antman, Joseph Loscalzo.
Nat Rev Cardiol, 2016 Jul 01; 13(10). PMID: 27356875
Highly Cited. Review.
Optimized adaptive enrichment designs.
Thomas Ondra, Sebastian Jobjörnsson, +4 authors, Martin Posch.
Stat Methods Med Res, 2017 Dec 20; 28(7). PMID: 29254436    Free PMC article.
Key enablers and barriers to implementing adaptive pathways in the European setting.
Juan Carlos Rejon-Parrilla, Pall Jonsson, Jacoline C Bouvy.
Br J Clin Pharmacol, 2019 Mar 09; 85(7). PMID: 30849187    Free PMC article.
Review.
Design of experiments for a confirmatory trial of precision medicine.
Kim May Lee, James Wason.
J Stat Plan Inference, 2019 Apr 23; 199. PMID: 31007363    Free PMC article.
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
Munyaradzi Dimairo, Philip Pallmann, +17 authors, ACE Consensus Group.
Trials, 2020 Jun 18; 21(1). PMID: 32546273    Free PMC article.
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.
Munyaradzi Dimairo, Philip Pallmann, +17 authors, ACE Consensus Group.
BMJ, 2020 Jun 20; 369. PMID: 32554564    Free PMC article.
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.
Linda Spiegelberg, Ruud Houben, +8 authors, Ludwig J Dubois.
Clin Transl Radiat Oncol, 2019 Feb 09; 15. PMID: 30734002    Free PMC article.
Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design.
Arinjita Bhattacharyya, Shesh N Rai.
Contemp Clin Trials Commun, 2019 Jul 11; 15. PMID: 31289760    Free PMC article.
Review.
Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials.
Jay Jh Park, Ofir Harari, +2 authors, Kristian Thorlund.
Contemp Clin Trials Commun, 2019 Jul 12; 15. PMID: 31294127    Free PMC article.
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.
Thomas Burnett, Pavel Mozgunov, +3 authors, Thomas Jaki.
BMC Med, 2020 Nov 20; 18(1). PMID: 33208155    Free PMC article.
Transforming clinical trials in rheumatology: towards patient-centric precision medicine.
Costantino Pitzalis, Ernest H S Choy, Maya H Buch.
Nat Rev Rheumatol, 2020 Sep 06; 16(10). PMID: 32887976
Review.
Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats.
Kim May Lee, Louise C Brown, +2 authors, James Wason.
Trials, 2021 Mar 12; 22(1). PMID: 33691748    Free PMC article.